Summarize and humanize this content to 2000 words in 6 paragraphs in English We recently published a list of 10 Best Long Term Growth Stocks to Buy According to Billionaires. In this article, we are going to take a look at where Moderna, Inc. (NASDAQ:MRNA) stands against other best long term growth stocks to buy according to billionaires. As per Barclays, the US administration announced numerous executive orders with reforms associated with world trade, immigration, and global geopolitics, resulting in elevated levels of uncertainty and volatility, with markets witnessing a range of policy changes. The firm’s research analysts opine that higher uncertainty comes at a cost to global growth. In the US, there has been a decline in consumer confidence, while personal spending remains weak, and GDP forecasts declined sharply, says the firm. S&P Global believes that the Trump administration’s shifting policy mix continues to result in a faster decline in growth in 2025. While the firm’s full-year growth rate remains unchanged at 1.9% (mainly because of higher base effects from a strong end to 2024), it expects a downshift in growth to 1.6% by Q4. It expects unemployment to drift higher, peaking at 4.6% by midyear 2026, with the public sector likely to limit the payroll expansion. This contrasts with strong contributions to job growth over the past 2 years. S&P Global expects inflation to remain closer to 3.0% in 2025 as tariffs result in higher prices along the domestic supply chain and for end consumers. Therefore, the company anticipates one 25-basis-point federal funds rate cut for 2025, closing the year at the 4.00%-4.25% range. READ ALSO: 7 Best Stocks to Buy For Long-Term and 8 Cheap Jim Cramer Stocks to Invest In. For 2025, Russell Investments expects a soft landing for the US economy. It assumes that the new administration will ease the more aggressive stances on tariffs and immigration. As per the firm, the US economy is projected to grow at a trend-like pace of 2.0% in 2025. The Trump administration’s policies exhibit a delicate balancing act. The firm believes that tax reforms and deregulation can help stimulate growth, mainly in domestic and cyclical sectors. Its working assumption is focused on the new administration not aggressively pursuing policies that result in inflation risk. While the tariffs and immigration controls are likely to be implemented, the firm opines that the extent is expected to be constrained by the inflation outlook. Overall, Russell Investments expects the policy mix to support business confidence, which can fuel a resurgence in capital markets and offer favorable tailwinds for private assets. Our Methodology To list the 10 Best Long Term Growth Stocks to Buy According to Billionaires, we used a screener and Insider Monkey’s exclusive database of billionaire stock holdings to shortlist the companies that have exhibited at least ~20% revenue growth over the past 5 years. For the stocks with the same number of billionaire holdings, we have used the number of hedge fund investors as a secondary metric to rank the stocks, as of Q4 2024. Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 373.4% since May 2014, beating its benchmark by 218 percentage points (see more details here). Is Moderna, Inc. (MRNA) the Best Long Term Growth Stock to Buy According to Billionaires? A scientist surrounded by vials and beakers in a modern laboratory, proudly displaying a vaccine. 5-Year Revenue Growth: ~122.01% Number of Billionaire Investors: 10 Number of Hedge Funds: 44 Moderna, Inc. (NASDAQ:MRNA) is a leader in the creation of the field of messenger RNA (mRNA) medicine. The company’s pipeline extends well beyond its COVID-19 vaccine, spanning across potential therapies and preventive measures. Moderna, Inc. (NASDAQ:MRNA) has announced that the Australian Therapeutic Goods Administration (TGA) approved mRESVIA® (mRNA-1345), which is an mRNA respiratory syncytial virus (RSV) vaccine, to prevent lower respiratory tract disease caused by RSV infection in adults aged 60 years and older. Notably, mRESVIA’s approval is a significant achievement as it is the first mRNA vaccine in Australia that is approved for use against a disease beyond COVID-19. The company has received marketing authorizations for its RSV vaccine in the US, the European Union, Canada, the United Arab Emirates, Qatar, Taiwan, and the United Kingdom. It has submitted regulatory applications in other markets worldwide. To provide a brief context, RSV is a highly contagious respiratory virus causing a substantial burden of disease, mainly in older adults. In 2025, Moderna, Inc. (NASDAQ:MRNA) remains focused on fueling sales and expanding cost efficiencies throughout the business. By 2025 end, it aims to remove ~$1 billion in costs. With robust momentum in its late-stage pipeline, Moderna, Inc. (NASDAQ:MRNA) expects multiple approvals starting this year, together with key Phase 3 readouts aiding its long-term growth. Overall, MRNA ranks 9th on our list of best long term growth stocks to buy according to billionaires. While we acknowledge the potential of MRNA as an investment, our conviction lies in the belief that some deeply undervalued AI stocks hold greater promise for delivering higher returns, and doing so within a shorter time frame. There is an AI stock that went up since the beginning of 2025, while popular AI stocks lost around 25%. If you are looking for a deeply undervalued AI stock that is more promising than MRNA but that trades at less than 5 times its earnings, check out our report about this cheapest AI stock. READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires. Disclosure: None. This article is originally published at Insider Monkey.
Keep Reading
